Medelis News - PRWeb Press Release Group http://www.prweb.com Medelis News - Powered by PRWeb en xml@emediawire.com xml@emediawire.com 30 Oncology Researchers Dr. Alan Sandler and Dr. James Cassidy Join Medical Advisory Board of Oncology CRO Medelis http://www.prweb.com/releases/oncology/cros/prweb2947114.htm Medelis, an oncology CRO providing contract research services for preclinical, phase I, phase II, and phase III oncology clinical trials in the US and Europe, has added two of the world's leading oncology researchers, Dr. Alan Sandler of Portland, Oregon and Dr. James Cassidy of Glasgow, Scotland, to its medical advisory board. (PRWeb Sep 29, 2009)

Read the full story at http://www.prweb.com/releases/oncology/cros/prweb2947114.htm

]]> Tue, 29 Sep 2009 07:00:00 GMT http://www.prweb.com/releases/oncology/cros/prweb2947114.htm Medelis Expands CRO Services to Medical Devices, Appoints Dr. Inder Makin as VP http://www.prweb.com/releases/contractresearch/medicaldevices/prweb2902524.htm Medelis, an oncology contract research organization in the US and Europe, is expanding its services to support medical devices under the guidance of Inder Makin, M.D., Ph.D., who joins the company as Vice President, Devices & Radiological Health. Medelis will support medical device manufacturers throughout the product life cycle including early design and prototyping, simulation, preclinical and phase I-III clinical studies. The company will also collaborate with clients to help them gain regulatory and marketing approvals. (PRWeb Sep 22, 2009)

Read the full story at http://www.prweb.com/releases/contractresearch/medicaldevices/prweb2902524.htm

]]> Tue, 22 Sep 2009 07:00:00 GMT http://www.prweb.com/releases/contractresearch/medicaldevices/prweb2902524.htm Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development http://www.prweb.com/releases/context-of-vulnerability/phase-I-phase-II-CRO/prweb2074494.htm Renowned cancer researcher Dr. Daniel Von Hoff and his team at TGen are fervent believers in a new approach to developing novel therapies for patients with pancreatic cancer. They are guided by a rationale dubbed the "context of vulnerability." Dr. Von Hoff provides case studies and explains how this powerful paradigm has already led to promising discoveries and is changing the future of oncology drug development. The complete interview is available for download from Medelis, an oncology contract research organization providing worldwide oncology clinical trial design, management and execution. (PRWeb Feb 17, 2009)

Read the full story at http://www.prweb.com/releases/context-of-vulnerability/phase-I-phase-II-CRO/prweb2074494.htm

]]> Tue, 17 Feb 2009 08:00:00 GMT http://www.prweb.com/releases/context-of-vulnerability/phase-I-phase-II-CRO/prweb2074494.htm Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' http://www.prweb.com/releases/oncology-clinical-trials/phase-I-trial-design/prweb1779564.htm Renowned oncology researcher Dr. Daniel Von Hoff, a member of President Bush's National Cancer Advisory Board, provides an in-depth look at the "lost opportunity" in phase I oncology clinical trials. While most biotechnology companies use the phase I trial to evaluate a drug's toxicity and tolerability, Dr. Von Hoff advocates that it can also provide valuable efficacy data and a compelling rationale for further study and investment, which ultimately lead to improved patient care. The complete interview is available for download from Medelis, an oncology contract research organization providing worldwide oncology clinical trial design, management and execution. (PRWeb Dec 22, 2008)

Read the full story at http://www.prweb.com/releases/oncology-clinical-trials/phase-I-trial-design/prweb1779564.htm

]]> Mon, 22 Dec 2008 08:00:00 GMT http://www.prweb.com/releases/oncology-clinical-trials/phase-I-trial-design/prweb1779564.htm Oncology CRO Adds Preclinical Research Services to Portfolio, Hires Dr. Mike McGarry as VP Preclinical Studies http://www.prweb.com/releases/cro/preclinicalresearch/prweb1305764.htm Medelis, Inc., an oncology contract research organization (CRO) providing drug development and clinical trial management services, today announced that Mike McGarry, Ph.D. has joined the company as Vice President of Preclinical Studies. Dr. McGarry, a preclinical research scientist with over 35 years of experience generating animal-based data, will lead a new service offering to provide preclinical program design, management and execution on behalf of Medelis' biotech clients around the world. (PRWeb Sep 9, 2008)

Read the full story at http://www.prweb.com/releases/cro/preclinicalresearch/prweb1305764.htm

]]> Tue, 09 Sep 2008 07:00:00 GMT http://www.prweb.com/releases/cro/preclinicalresearch/prweb1305764.htm Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development http://www.prweb.com/releases/cros/preclinicalstudies/prweb1242484.htm Medelis, an oncology contract research organization, has published a free abstract, "Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster." In the abstract, Dr. Mike McGarry, a preclinical research scientist with 35 years of experience, discusses how oncology preclinical studies are commonly viewed as straightforward investigations run exclusively by researchers who operate without true integration with preclinical, regulatory and clinical teams. He describes a nuanced preclinical study process that hinges on a well-defined rodent model, quality data, and ongoing integration between the preclinical, regulatory and clinical teams. (PRWeb Sep 4, 2008)

Read the full story at http://www.prweb.com/releases/cros/preclinicalstudies/prweb1242484.htm

]]> Thu, 04 Sep 2008 07:00:00 GMT http://www.prweb.com/releases/cros/preclinicalstudies/prweb1242484.htm Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit http://www.prweb.com/releases/cros/dan-von-hoff/prweb1066724.htm Renowned oncology researcher Dr. Daniel Von Hoff, a member of President Bush's National Cancer Advisory Board, provides an in-depth look at "The Complete Phase Ib," an oncology clinical trial design that creates rapid accrual rates, substantial economies of scale, significant time savings, enthusiasm from investigators and patients, and improved therapeutic benefits. The complete interview is available for download from Medelis, a contract research organization providing complete oncology clinical trial design, management and execution. (PRWeb Jul 9, 2008)

Read the full story at http://www.prweb.com/releases/cros/dan-von-hoff/prweb1066724.htm

]]> Wed, 09 Jul 2008 07:00:00 GMT http://www.prweb.com/releases/cros/dan-von-hoff/prweb1066724.htm Oncology CRO Publishes Free "Patient Safety in Oncology Clinical Trials" Abstract for Chief Medical Officers http://www.prweb.com/releases/2008/03/prweb771884.htm Patient safety has always been the industry's focus during clinical trials. However, a recent spate of well-publicized patient safety issues has increased public scrutiny and the industry's desire to improve study quality, resulting in larger, longer, more expensive trials. In "Patient Safety in Oncology Clinical Trials," Dr. James Gourzis discusses patient safety as it pertains specifically to oncology clinical trials. The abstract is available for download on the Medelis Oncology CRO website. (PRWeb Mar 25, 2008)

Read the full story at http://www.prweb.com/releases/2008/03/prweb771884.htm

]]> Tue, 25 Mar 2008 07:00:00 GMT http://www.prweb.com/releases/2008/03/prweb771884.htm